A vs VRTX
Agilent Technologies vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
A
Agilent Technologies
65
Buy
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | A | VRTX |
|---|
| AI Score |
65
|
67
|
| Price |
$146.09
|
$496.21
|
| P/E Ratio |
29.25×
|
28.64×
|
| ROE |
19.3%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
53.0%
|
86.0%
|
| Debt / Equity |
0.47×
|
0.00×
|
| Dividend Yield |
0.7%
|
0.0%
|
| RSI (14) |
79.0
|
66.6
|
| Beta |
1.255
|
0.292
|
| Expected Upside |
+2.0%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for A versus VRTX.
VRTX leads by 2 points.
VRTX scores 67/100 (Buy) versus A at 65/100 (Buy).
A Committee View
83% agreement
6 analysts
The primary driver is news sentiment is positive (+0.40 across 28 articles, 14d). The main limiting factor is p/e of 29.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.2 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 79 is in overbought territory — Technical
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical